Antihypertensive effects of perindopril treatment in adult spontaneously hypertensive rats

Canadian Journal of Cardiology

Volumn 13, Issue 9, 1997, Pages 831-835

  Lee, Robert M K W ^a   Lu, Mei ^a   Gillies, Leesa ^a   Werstiuk, Eva S ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiotensin converting enzyme activity; Blood pressure; Hypertension; Perindopril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN; PERINDOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG WITHDRAWAL; ENZYME ACTIVITY; HEART RATE; HYPERTENSION; MALE; NONHUMAN; NORADRENALIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; RADIOASSAY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; INDOLES; MALE; NOREPINEPHRINE; PEPTIDYL-DIPEPTIDASE A; PERINDOPRIL; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TIME FACTORS;

EID: 0030782065     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Schachter M. Drug-induced modification of vascular structure: Effects of antihypertensive drugs. Am Heart J 1991;122:16-23.
2. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin 1-converting enzyme inhibitor: Comparison with effects of a β-blocker. Am J Hypertens 1995;8:229-36.
3. Mulvany MJ. The development and regression of vascular hypertrophy. J Cardiovasc Pharmacol 1992;19:S22-7.
4. Korner PI, Bobik A, Jennings GL, Angus JA, Anderson WP. Significance of cardiovascular hypertrophy in the development and maintenance of hypertension. J Cardiovasc Pharmacol 1991;17 S25-32.
5. Sihm I, Shroeder AP, Aalkjær C, et al. Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients. Am J Cardiol 1995;76:38E-40E.
6. Cadilhac M, Giudicelli JF. Myocardial and vascular effects of perindopril, a new converting enzyme inhibitor, during hypertension development in spontaneously hypertensive rats. Arch Int Pharmacodyn 1986;234:114-26.
7. Christensen HRL, Nielsen H, Christensen KL, Baandrup U, Jespersen LT, Mulvany MJ. Long-term hypertensive effects of an angiotensin converting enzyme inhibitor in spontaneously hypertensive rats: Is there a role for vascular structure? J Hypertens 1988;6(Suppl 3): S27-31.
8. Adams MA, Bobik A, Korner PI. Enalapril can prevent vascular amplifier development in spontaneously hypertensive rats. Hypertension 1990;16:252-60.
9. Christensen KL, Jespersen LT, Mulvany MJ. Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertens 1989;7:83-90.
10. Harrap SB, Van der Merwe WM, Griffin SA, MacPherson F, Lever AF. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990;16:603-14.
11. Mulvany MJ. Is there a role for the vascular renin-angiotensin system in the determination of vascular structure. Blood Vessels 1991;28:224-30.
12. Thybo NK, Korsgaard N, Eriksen S, Christensen KL, Mulvany MJ. Dose-dependent effects of perindopril on blood pressure and small-artery structure. Hypertension 1994;23:659-66.
13. King RA, Smith RM, Krishnan R, Cleary EG. Effects of enalapril and hydralazine treatment and withdrawal upon cardiovascular hypertrophy in stroke-prone spontaneously hypertensive rats. J Hypertens 1992;10:919-28.
14. Unger T, Ganten D, Lang RE, Scholkens BA. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1985;7:36-41.
15. Unger T, Moursi M, Ganten D, Hermann K, Lang RE. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: Comparison with enalapril (MK421) and ramipril (HOE498). J Cardiovasc Pharmacol 1986;8:276-85.
16. Lee RMKW, Delaney KH, Lu M. Perindopril treatment prolonged the lifespan of spontaneously hypertensive rats. J Hypertens 1995;13:471-6.
17. Lee RMKW, Berecek KH, Tsoporis J, McKenzie R, Tnggle CR. Prevention of hypertension and vascular changes by captopril treatment. Hypertension 1991;17:141-50.
18. Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1971;20:1637-48.
19. Chiu AT, McCall DE, Price WA, et al. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:711-8.
20. Ryan JW, Chung A, Ammons C, Carlton ML. A Simple radioassay for angiotensin-converting enzyme. Biochem J 1977;167:501-4.
21. Lee RMKW, Wang H, Smeda JS. Perindopril treatment in the prevention of stroke in experimental animals. J Hypertens 1996;14:S29-33.
22. Jouquey S, Stepniewski JP, Hamon G. Trandolapril dose-response in spontaneously hypertensive rats: Effects on ACE activity, blood pressure, and cardiac hypertrophy. J Cardiovasc Pharmacol 1994;23(Suppl 4):S16-8.